search  
 


Home

Who are we?

Why
register?


Signup for
registration


Online registration

Log in to register
your trial


Search a trial

NRT en CCMO

Contact

NEDERLANDS





MetaRegister
van CCT (UK)


ISRCTN-Register
van CCT (UK)


11C-Methionin (MET) PET vs 18F-FDG PET in the follow-up of differentiated thyroid cancer.


- candidate number6285
- NTR NumberNTR1937
- ISRCTNISRCTN wordt niet meer aangevraagd.
- Date ISRCTN created
- date ISRCTN requested
- Date Registered NTR6-aug-2009
- Secondary IDs2008/231 METC UMC Groningen
- Public Title11C-Methionin (MET) PET vs 18F-FDG PET in the follow-up of differentiated thyroid cancer.
- Scientific Title11C-MET PET(/CT) vs 18F-FDG PET(/CT) in the follow-up of differentiated thyroid cancer.
- ACRONYMMET PET vs FDG PET in DTC
- hypothesis1. To evaluate the clinical performance of MET PET during rhTSH stimulation and to compare the results of the rhTSH stimulated MET PET with the standard rhTSH stimulated FDG PET in patients with negative post-treatment 131-I scans and elevated serum thyroglobulin (Tg);
2. To evaluate the (complementary) value of MET PET in patients with persistent or recurrent Hürthlecell carcinoma in the post-ablation phase and during follow-up.
- Healt Condition(s) or Problem(s) studiedDifferentiated thyroid carcinoma, 11-C Methionine PET
- Inclusion criteriaObjective (study) 1:
1. > 18 years old;
2. Total thyroidectomy;
3. Negative post-treatment 131I-WBS with elevated Tg(on) (>5.0 ng.ml);
4. Signed informed consent.

Objective (study) 2:
1. > 18 years old;
2. Total thyroidectomy;
3. Patients with persistent or recurrent Hürthlecell carcinoma in post-ablation phase or during follow-up;
4. Signed informed consent.
- Exclusion criteriaBoth objectives/studies:
1. Pregnancy;
2. Patients with any signs of neurological or psychiatric disorders that will preclude him/her from expressing her/his own free will.
- mec approval receivedyes
- multicenter trialno
- randomisedno
- groupParallel
- TypeSingle arm
- Studytypeobservational
- planned startdate 9-jan-2009
- planned closingdate9-jan-2012
- Target number of participants25
- Interventions11C-MET PET scan.
- Primary outcomeA qualitative and semi-quantitative (standardized uptake values (SUVs)) reading of all the PET studies will be performed. Comparison with data derived from clinical CT imaging data, and where feasible histological or cytological confirmation, will take place.

Objective/Study 1:
The results of 11C-MET PET will be compared with the clinical FDG PET.
Objective/Study 2:
The results of 11C-MET PET will be compared with the clinical FDG PET.
The results of both PET scan will also be compared with the (diagnostic and) post-treatment 131I-WBS.
- Secondary outcomeNo secondary outcomes.
- TimepointsNo additional time point. 11C-MET PET scan will be combined with 18 FDG PET scan.
- Trial web siteN/A
- statusopen: patient inclusion
- CONTACT FOR PUBLIC QUERIESDr. T.P. Links
- CONTACT for SCIENTIFIC QUERIESDr. T.P. Links
- Sponsor/Initiator University Medical Center Groningen (UMCG)
- Funding
(Source(s) of Monetary or Material Support)
University Medical Center Groningen (UMCG)
- PublicationsN/A
- Brief summaryAlthough FDG PET(/CT), under TSH stimulation, is now considered as a valuable, established diagnostic imaging tool in the follow-up of 131I-negative patients for the detection of recurrences or metastases, the interest for new tracers and improvement of diagnostic tools in thyroid cancer is growing. Another target for metabolic tumor imaging is the increased protein metabolism and transport in cancer cells, to which radiolabeled amino acids can be applied. Amino acid transport is generally increased in malignant tissue, which could be associated with specific cell surface changes in transformed cells. The process of malignant transformation requires in general that cells acquire and use nutrients efficiently for energy, protein synthesis and cell division. Two major steps are involved in protein metabolism including increased amino acid transport and protein synthesis. It is imaginable that thyroid cancer could sufficiently concentrate amino acids due to its protein synthesis (e.g. thyroglobulin) and the often slowly progressive character in the well-differentiated tumors (e.g. Hurthlecell carcinoma).
The general feasibility of amino acid imaging with C-11 methionine (MET) PET under TSH suppression in differentiated thyroid cancer (DTC) has been shown (Phan et al, in press NMC). Interesting finding in the study of Phan et al. was the complementary uptake of MET and FDG in 25% of the patients. It has been hypothesized that this finding might be explained by the degree of tissue dedifferentiation. Hürthlecell carcinoma are known to be less radioiodine-avid compared to the well-differentiated papillary and follicular carcinoma or can be even non-iodine or non-FDG avid. For this group of patients MET PET might be of complementary value.
In-vitro study in the rat thyroid cells has suggested that the TSH level does not influence the amino acid uptake. However, no clinical intra-individually comparative studies between 18F-FDG PET and 11C-MET PET during (rh)TSH stimulation are available. It would be of interest to evaluate the diagnostic yield of MET PET scans under (recombinant human, rh)TSH stimulation and to compare these results with TSH stimulated FDG PET.
- Main changes (audit trail)
- RECORD6-aug-2009 - 11-okt-2009


  • Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar nederlands@trialregister.nl